Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 686–687 (2007)Cite this article

boxed-textBlack DM et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927–2938

Continued alendronate therapy beyond 5 years has sustained antifracture efficacy and seems to be safe; patients at high fracture risk should, therefore, remain on therapy, whereas low-risk patients could stop therapy after 5 years

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nancollas GH et al. (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617–627

    Article  CAS  Google Scholar 

  2. Odvina CV et al. (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294–1301

    Article  CAS  Google Scholar 

  3. Ruffoni D et al. (2007) The bone mineralization density distribution as a fingerprint of the mineralization process. Bone 40: 1308–1319

    Article  CAS  Google Scholar 

  4. Mellström DD et al. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462–468

    Article  Google Scholar 

  5. Bone HG et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. ME Kraenzlin and C Meier are both Consultants in the Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.,

    Marius E Kraenzlin & Christian Meier

Authors
  1. Marius E Kraenzlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marius E Kraenzlin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kraenzlin, M., Meier, C. Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?. Nat Rev Endocrinol 3, 686–687 (2007). https://doi.org/10.1038/ncpendmet0618

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0618

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing